Bart Vandesompele

Ziphius Vaccines NV is a Belgian biopharmaceutical company that specializes in developing vaccines and therapeutics using its proprietary self-amplifying RNA and carrier technology platforms. The private company is based in Ghent, Belgium and has a portfolio of next-generation vaccine candidates that target infectious diseases and gene supplementation therapies. The company's lead compound, Zip1642, is a COVID-19 vaccine candidate that has undergone preclinical studies. The company was founded in 2019 by Christian Cardon, who has been the CEO since then.

Part of Post Verba Verbera NV, AnaBioTec NV is a Belgian-based analytical service provider that focuses on small molecules, biologics, biosimilars, cell and gene therapy solutions. The company is based in Evergem, Belgium. AnaBioTec provides analytical insight during CMC activities for product development and filing. With over 20 years of experience in analytical method development and validation, the Belgian company helps mitigate risks and accelerate timelines. The company's experienced scientific project managers connect the dots in projects and anticipate where needed to safeguard milestones. AnaBioTec has extensive experience with DS, complex formulations/mixtures, liposomal products, low solubility products, microspheres, and derivatized products. The company offers small molecule solutions, biologics solutions, and cell and gene therapy solutions. The company was founded in 1983 by Griet Nuytinck.